- Home
- LEU vs EYPT Comparison
LEU vs EYPT Comparison
Compare LEU & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- EYPT
- Stock Information
- Founded
- LEU 1998
- EYPT 1987
- Country
- LEU United States
- EYPT United States
- Employees
- LEU N/A
- EYPT N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- LEU Industrials
- EYPT Industrials
- Exchange
- LEU Nasdaq
- EYPT Nasdaq
- Market Cap
- LEU 4.2B
- EYPT 741.0M
- IPO Year
- LEU 1998
- EYPT 2005
- Fundamental
- Price
- LEU $222.17
- EYPT $13.35
- Analyst Decision
- LEU Buy
- EYPT Strong Buy
- Analyst Count
- LEU 11
- EYPT 6
- Target Price
- LEU $194.80
- EYPT $25.83
- AVG Volume (30 Days)
- LEU 1.2M
- EYPT 783.3K
- Earning Date
- LEU 10-27-2025
- EYPT 11-06-2025
- Dividend Yield
- LEU N/A
- EYPT N/A
- EPS Growth
- LEU 10.12
- EYPT N/A
- EPS
- LEU 6.16
- EYPT N/A
- Revenue
- LEU $436,900,000.00
- EYPT $51,898,000.00
- Revenue This Year
- LEU $3.52
- EYPT N/A
- Revenue Next Year
- LEU $8.01
- EYPT N/A
- P/E Ratio
- LEU $36.09
- EYPT N/A
- Revenue Growth
- LEU 12.72
- EYPT 2.99
- 52 Week Low
- LEU $38.77
- EYPT $3.91
- 52 Week High
- LEU $264.90
- EYPT $14.42
- Technical
- Relative Strength Index (RSI)
- LEU 59.71
- EYPT 63.75
- Support Level
- LEU $214.00
- EYPT $13.19
- Resistance Level
- LEU $232.67
- EYPT $14.42
- Average True Range (ATR)
- LEU 13.65
- EYPT 0.77
- MACD
- LEU 3.29
- EYPT 0.11
- Stochastic Oscillator
- LEU 78.24
- EYPT 66.14
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.